

M Hong Nguyen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6493977/publications.pdf>

Version: 2024-02-01

98
papers

7,211
citations

87843

38
h-index

58549

82
g-index

100
all docs

100
docs citations

100
times ranked

7610
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Epidemiology, Natural History, and Long-Term Outcomes of Multidrug-Resistant Enterobacteriales Colonization and Infections Among Solid Organ Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2022, 74, 395-406.	2.9	19
2	Candidemia Among Coronavirus Disease 2019 Patients in Turkey Admitted to Intensive Care Units: A Retrospective Multicenter Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac078.	0.4	13
3	Coronavirus Disease 2019-Associated Pulmonary Aspergillosis: Reframing the Debate. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac081.	0.4	6
4	Screening for Ocular Candidiasis Among Patients With Candidemia: Is It Time to Change Practice?. <i>Clinical Infectious Diseases</i> , 2022, 75, 1092-1096.	2.9	9
5	Climate events and return comovement. <i>Journal of Financial Markets</i> , 2022, 61, 100731.	0.7	5
6	Reply to Breazzano et al. <i>Clinical Infectious Diseases</i> , 2022, 75, 1271-1272.	2.9	1
7	Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2021, 73, 416-426.	2.9	37
8	Impact of Revised Infectious Diseases Society of America and Society for Healthcare Epidemiology of America Clinical Practice Guidelines on the Treatment of <i>Clostridium difficile</i> Infections in the United States. <i>Clinical Infectious Diseases</i> , 2021, 72, 1944-1949.	2.9	31
9	Antibacterial Drug Development Trends in the United States from 1980 to 2019: Agents Active Against Carbapenem-resistant Gram-negative Bacteria as Case Study. <i>Clinical Infectious Diseases</i> , 2021, 72, e437-e438.	2.9	0
10	Air pollution and behavioral biases: Evidence from stock market anomalies. <i>Journal of Behavioral and Experimental Finance</i> , 2021, 29, 100441.	2.1	11
11	A First Draft of the History of Treating Coronavirus Disease 2019: Use of Repurposed Medications in United States Hospitals. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa617.	0.4	2
12	Country governance and international equity returns. <i>Journal of Banking and Finance</i> , 2021, 122, 105986.	1.4	8
13	Reply to Turner. <i>Clinical Infectious Diseases</i> , 2021, 72, 2065-2066.	2.9	0
14	Fungal infections in lung transplantation. <i>Journal of Thoracic Disease</i> , 2021, 13, 6695-6707.	0.6	13
15	Bacterial Superinfections Among Persons With Coronavirus Disease 2019: A Comprehensive Review of Data From Postmortem Studies. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab065.	0.4	54
16	Do accounting information and market environment matter for cross-asset predictability?. <i>Accounting and Finance</i> , 2021, 61, 4389-4434.	1.7	0
17	Does investor attention matter for market anomalies?. <i>Journal of Behavioral and Experimental Finance</i> , 2021, 29, 100451.	2.1	7
18	<i>Candida</i> Empyema Thoracis at Two Academic Medical Centers: New Insights Into Treatment and Outcomes. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa656.	0.4	16

#	ARTICLE	IF	CITATIONS
19	<i>In Vitro</i> Susceptibility of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> following Treatment-Emergent Resistance to Ceftolozane-Tazobactam. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	31
20	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. <i>Intensive Care Medicine</i> , 2021, 47, 819-834.	3.9	106
21	Pervasive but Neglected: A Perspective on COVID-19-Associated Pulmonary Mold Infections Among Mechanically Ventilated COVID-19 Patients. <i>Frontiers in Medicine</i> , 2021, 8, 649675.	1.2	18
22	Invasive mould disease in fatal COVID-19: a systematic review of autopsies. <i>Lancet Microbe</i> , The, 2021, 2, e405-e414.	3.4	62
23	Trends in Outpatient Antibiotic Prescriptions in the United States During the COVID-19 Pandemic in 2020. <i>JAMA Network Open</i> , 2021, 4, e2126114.	2.8	33
24	Do climate risks matter for green investment?. <i>Journal of International Financial Markets, Institutions and Money</i> , 2021, 75, 101438.	2.1	18
25	Invasive Pulmonary Aspergillosis Complicating Noninfluenza Respiratory Viral Infections in Solid Organ Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab478.	0.4	9
26	Bribe or die: gender differences in entrepreneurship in emerging markets. <i>Applied Economics</i> , 2021, 53, 2170-2191.	1.2	8
27	Discordance Among Antibiotic Prescription Guidelines Reflects a Lack of Clear Best Practices. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa571.	0.4	1
28	Coronavirus Disease 2019-associated Invasive Fungal Infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab510.	0.4	75
29	Sequence type-258 carbapenem-resistant <i>Klebsiella pneumoniae</i> isolates in which ceftazidime-avibactam resistance emerged are not hypermutators. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 96, 114954.	0.8	1
30	Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections. <i>Clinical Infectious Diseases</i> , 2020, 71, 667-671.	2.9	71
31	PRO: The COVID-19 pandemic will result in increased antimicrobial resistance rates. <i>JAC-Antimicrobial Resistance</i> , 2020, 2, dlaa049.	0.9	67
32	COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions?. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 211.	1.5	170
33	Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3023-3028.	1.3	13
34	Epidemiologic and Microbiologic Characteristics of Hospitalized Patients Co-colonized With Multiple Species of Carbapenem-Resistant Enterobacteriaceae in the United States. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa386.	0.4	6
35	It's worse than we thought: the US market for novel Gram-negative antibiotics. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1009-1010.	4.6	4
36	Antibiotic Consumption and Stewardship at a Hospital outside of an Early Coronavirus Disease 2019 Epicenter. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	39

#	ARTICLE	IF	CITATIONS
37	Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect?. <i>Clinical Infectious Diseases</i> , 2020, 71, 2736-2743.	2.9	203
38	Population Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	18
39	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. <i>Intensive Care Medicine</i> , 2020, 46, 1524-1535.	3.9	278
40	Invasive Aspergillosis as an Under-recognized Superinfection in COVID-19. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa242.	0.4	62
41	What Is New in Candida Infections? T2Candida, Antifungal Stewardship, and Candida auris. <i>Current Treatment Options in Infectious Diseases</i> , 2020, 12, 1-12.	0.8	0
42	Buying Time: The AMR Action Fund and the State of Antibiotic Development in the United States 2020. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa464.	0.4	14
43	Impact of the Coronavirus Disease 2019 Pandemic on Outpatient Antibiotic Prescriptions in the United States. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa575.	0.4	38
44	Genetic diversity of clinical and environmental Mucorales isolates obtained from an investigation of mucormycosis cases among solid organ transplant recipients. <i>Microbial Genomics</i> , 2020, 6, .	1.0	10
45	Estimating the Size of the U.S. Market for New Antibiotics with Activity against Carbapenem-Resistant <i>Enterobacteriaceae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	22
46	Estimating the Treatment of Carbapenem-Resistant <i>Enterobacteriaceae</i> Infections in the United States Using Antibiotic Prescription Data. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz344.	0.4	51
47	Pharmacodynamics of Ceftazidime plus Avibactam against KPC-2-Bearing Isolates of <i>Klebsiella pneumoniae</i> in a Hollow Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	13
48	Effects of KPC Variant and Porin Genotype on the <i>In Vitro</i> Activity of Meropenem-Vaborbactam against Carbapenem-Resistant <i>Enterobacteriaceae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	61
49	Spontaneous Mutational Frequency and <i>FKS</i> Mutation Rates Vary by Echinocandin Agent against <i>Candida glabrata</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	30
50	Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant <i>Enterobacteriaceae</i> Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	203
51	T2 magnetic resonance for the diagnosis of bloodstream infections: charting a path forward. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, iv2-iv5.	1.3	65
52	Efficacy of T2 Magnetic Resonance Assay in Monitoring Candidemia after Initiation of Antifungal Therapy: the Serial Therapeutic and Antifungal Monitoring Protocol (STAMP) Trial. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	61
53	Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel. <i>Clinical Infectious Diseases</i> , 2018, 66, 1678-1686.	2.9	129
54	PCR-Based Methods for the Diagnosis of Invasive Candidiasis: Are They Ready for Use in the Clinic?. <i>Current Fungal Infection Reports</i> , 2018, 12, 71-77.	0.9	1

#	ARTICLE	IF	CITATIONS
55	Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> . <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	55
56	Politics and liquidity. <i>Journal of Financial Markets</i> , 2018, 38, 1-13.	0.7	11
57	Pharmacokinetics of Azole Antifungals in Cystic Fibrosis. <i>Mycopathologia</i> , 2018, 183, 139-150.	1.3	21
58	Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	29
59	Non-Culture Diagnostics for Invasive Candidiasis: Promise and Unintended Consequences. <i>Journal of Fungi (Basel, Switzerland)</i> , 2018, 4, 27.	1.5	49
60	When are extreme daily returns not lottery? At earnings announcements!. <i>Journal of Financial Markets</i> , 2018, 41, 92-116.	0.7	16
61	Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	22
62	Mutations in <i>bla</i> _{KPC-3} That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β ² -Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	154
63	In Vitro Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible <i>Klebsiella pneumoniae</i> Isolates with Variant KPC-3 Carbapenemases. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	84
64	Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	122
65	Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	347
66	Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections: Clinical Effectiveness and Evolution of Resistance. <i>Clinical Infectious Diseases</i> , 2017, 65, 110-120.	2.9	224
67	Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne <i>bla</i> _{KPC-3} Mutations during Treatment of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	334
68	Pathogenesis of Invasive Pulmonary Aspergillosis in Transplant Recipients. <i>Current Fungal Infection Reports</i> , 2017, 11, 148-157.	0.9	1
69	Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	36
70	Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	72
71	Emergence of <i>Candida auris</i> : An International Call to Arms. <i>Clinical Infectious Diseases</i> , 2017, 64, 141-143.	2.9	106
72	Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in <i>Klebsiella pneumoniae</i> Carbapenemase-Producing <i>K pneumoniae</i> : A Case Report and Review of Literature. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx101.	0.4	103

#	ARTICLE	IF	CITATIONS
73	Candida albicans Transcriptional Profiling Within Biliary Fluid From a Patient With Cholangitis, Before and After Antifungal Treatment and Surgical Drainage. Open Forum Infectious Diseases, 2016, 3, ofw120.	0.4	0
74	Invasive Candidiasis in Various Patient Populations: Incorporating Non-Culture Diagnostic Tests into Rational Management Strategies. Journal of Fungi (Basel, Switzerland), 2016, 2, 10.	1.5	10
75	Pharmacokinetics of Posaconazole Suspension in Lung Transplant Patients with and without Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 3558-3562.	1.4	14
76	Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2016, 63, e1-e60.	2.9	1,861
77	Highly Dynamic and Specific Phosphatidylinositol 4,5-Bisphosphate, Septin, and Cell Wall Integrity Pathway Responses Correlate with Caspofungin Activity against Candida albicans. Antimicrobial Agents and Chemotherapy, 2016, 60, 3591-3600.	1.4	18
78	Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2016, 60, 3187-3192.	1.4	41
79	Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2016, 63, 433-442.	2.9	295
80	Rapid Detection of <i>FKS</i> -Associated Echinocandin Resistance in Candida glabrata. Antimicrobial Agents and Chemotherapy, 2016, 60, 6573-6577.	1.4	53
81	Association between the Presence of Aminoglycoside-Modifying Enzymes and <i>In Vitro</i> Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against Klebsiella pneumoniae Carbapenemase- and Extended-Spectrum β -Lactamase-Producing Enterobacter Species. Antimicrobial Agents and Chemotherapy, 2016, 60, 5208-5214.	1.4	38
82	Evaluation of the <i>In Vitro</i> Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates. Antimicrobial Agents and Chemotherapy, 2016, 60, 3227-3231.	1.4	85
83	Coordination of Candida albicans Invasion and Infection Functions by Phosphoglycerol Phosphatase Rhr2. Pathogens, 2015, 4, 573-589.	1.2	21
84	Diagnostic Modalities for Invasive Mould Infections among Hematopoietic Stem Cell Transplant and Solid Organ Recipients: Performance Characteristics and Practical Roles in the Clinic. Journal of Fungi (Basel, Switzerland), 2015, 1, 252-276.	1.5	4
85	Doripenem MICs and ompK36 Porin Genotypes of Sequence Type 258, KPC-Producing Klebsiella pneumoniae May Predict Responses to Carbapenem-Colistin Combination Therapy among Patients with Bacteremia. Antimicrobial Agents and Chemotherapy, 2015, 59, 1797-1801.	1.4	25
86	Effects of Klebsiella pneumoniae Carbapenemase Subtypes, Extended-Spectrum β -Lactamases, and Porin Mutations on the <i>In Vitro</i> Activity of Ceftazidime-Avibactam against Carbapenem-Resistant K. pneumoniae. Antimicrobial Agents and Chemotherapy, 2015, 59, 5793-5797.	1.4	104
87	Rate of <i>FKS</i> Mutations among Consecutive Candida Isolates Causing Bloodstream Infection. Antimicrobial Agents and Chemotherapy, 2015, 59, 7465-7470.	1.4	48
88	Delinking CARD9 and IL-17: CARD9 Protects against <i>Candida tropicalis</i> Infection through a TNF- α -Dependent, IL-17-Independent Mechanism. Journal of Immunology, 2015, 195, 3781-3792.	0.4	38
89	Abdominal Candidiasis Is a Hidden Reservoir of Echinocandin Resistance. Antimicrobial Agents and Chemotherapy, 2014, 58, 7601-7605.	1.4	89
90	KPC-Producing Klebsiella pneumoniae Strains That Harbor AAC(6)-Ib Exhibit Intermediate Resistance to Amikacin. Antimicrobial Agents and Chemotherapy, 2014, 58, 7597-7600.	1.4	17

#	ARTICLE	IF	CITATIONS
91	Doripenem, Gentamicin, and Colistin, Alone and in Combinations, against Gentamicin-Susceptible, KPC-Producing <i>Klebsiella pneumoniae</i> Strains with Various <i>ompK36</i> Genotypes. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3521-3525.	1.4	34
92	Mutational Analysis of Essential Septins Reveals a Role for Septin-Mediated Signaling in Filamentation. <i>Eukaryotic Cell</i> , 2014, 13, 1403-1410.	3.4	9
93	<i>Candida glabrata</i> Intra-Abdominal Candidiasis Is Characterized by Persistence within the Peritoneal Cavity and Abscesses. <i>Infection and Immunity</i> , 2014, 82, 3015-3022.	1.0	36
94	Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Strains Exhibit Diversity in Aminoglycoside-Modifying Enzymes, Which Exert Differing Effects on Plazomicin and Other Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4443-4451.	1.4	99
95	Performance of <i>Candida</i> Real-time Polymerase Chain Reaction, β -D-Glucan Assay, and Blood Cultures in the Diagnosis of Invasive Candidiasis. <i>Clinical Infectious Diseases</i> , 2012, 54, 1240-1248.	2.9	247
96	A 62-Year-Old Male Heart Transplant Recipient With Progressive Hypoxia. <i>Chest</i> , 2011, 139, 954-957.	0.4	1
97	Bank performance during the credit crisis: evidence from Asia-Pacific countries. <i>Applied Economics Letters</i> , 0, , 1-14.	1.0	3
98	Systemic Candidiasis: Candidemia and Deep-Organ Infections. , 0, , 429-441.		3